生物股份非瘟亚单位疫苗临床试验获批，创新龙头成长动能强劲

开源证券2025-07-18

一、非瘟亚单位疫苗临床试验获批，创新龙头成长动能强劲生物股份全资子公司金宇保灵于2025年7月17日收到农业农村部颁发的非瘟亚单位疫苗临床试验批件。该款疫苗由中科院生物物理所、金宇保灵及中牧股份等6家机构合作研发，是目前我国唯一一款获得临床试验批件的非瘟亚单位疫苗。公司依托P3实验室建立非洲猪瘟疫苗集成研发平台，并获得相关病原微生物活动资质，成为本轮临床试验唯一承担单位，彰显强大的研发实力。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552461692?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-18 18:16","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552461692","market":"sh","top_or_hot":-1,"title":"生物股份非瘟亚单位疫苗临床试验获批，创新龙头成长动能强劲","media":"开源证券","content":"<div>\n<p>一、非瘟亚单位疫苗临床试验获批，创新龙头成长动能强劲生物股份 全资子公司金宇保灵于2025年7月17日收到农业农村部颁发的非瘟亚单位疫苗临床试验批件。该款疫苗由中科院生物物理所、金宇保灵及 中牧股份 等6家机构合作研发，是目前我国唯一一款获得临床试验批件的非瘟亚单位疫苗。公司依托P3实验室建立非洲猪瘟疫苗集成研发平台，并获得相关病原微生物活动资质，成为本轮临床试验唯一承担单位，彰显强大的研发实力。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718183020a6b1f777&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>生物股份非瘟亚单位疫苗临床试验获批，创新龙头成长动能强劲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n生物股份非瘟亚单位疫苗临床试验获批，创新龙头成长动能强劲\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-18 18:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718183020a6b1f777&s=b><strong>开源证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一、非瘟亚单位疫苗临床试验获批，创新龙头成长动能强劲生物股份 全资子公司金宇保灵于2025年7月17日收到农业农村部颁发的非瘟亚单位疫苗临床试验批件。该款疫苗由中科院生物物理所、金宇保灵及 中牧股份 等6家机构合作研发，是目前我国唯一一款获得临床试验批件的非瘟亚单位疫苗。公司依托P3实验室建立非洲猪瘟疫苗集成研发平台，并获得相关病原微生物活动资质，成为本轮临床试验唯一承担单位，彰显强大的研发实力。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718183020a6b1f777&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718183020a6b1f777&s=b","article_id":"2552461692","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718183020a6b1f777&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552461692","pubTimestamp":1752833764,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"该款疫苗由中科院生物物理所、金宇保灵及 中牧股份 等6家机构合作研发，是目前我国唯一一款获得临床试验批件的非瘟亚单位疫苗。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","600195":"中牧股份","600201":"生物股份","BK0046":"生物疫苗","BK0028":"国家队","BK0010":"央企","BK0168":"禽流感","BK0185":"二线龙头","BK0239":"医药制造","BK0188":"融资融券","BK0077":"质押式回购","BK0012":"证金概念","BK0196":"行业龙头"},"translate_title":"The clinical trial of ASF subunit vaccine of Biotech Co., Ltd. was approved, and the innovation leader has strong growth momentum","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"600195":0.9,"600201":1},"content_text":"一、非瘟亚单位疫苗临床试验获批，创新龙头成长动能强劲生物股份 全资子公司金宇保灵于2025年7月17日收到农业农村部颁发的非瘟亚单位疫苗临床试验批件。该款疫苗由中科院生物物理所、金宇保灵及 中牧股份 等6家机构合作研发，是目前我国唯一一款获得临床试验批件的非瘟亚单位疫苗。公司依托P3实验室建立非洲猪瘟疫苗集成研发平台，并获得相关病原微生物活动资质，成为本轮临床试验唯一承担单位，彰显强大的研发实力。二、短期业绩承压，但深化改革推动盈利修复公司在2025年上半年归母净利润预计为0.57亿至0.70亿元，同比下滑53.63%至43.05%，其中2025年Q2亏损0.19亿至0.06亿元。业绩下滑主要由于人用抗体药物研发费用及无形资产折旧摊销大幅增加，同时行业竞争加剧。公司积极通过深化改革提质增效，以应对短期压力并推动盈利修复。三、非瘟疫苗与新品推进，开启长期成长空间公司的非瘟亚单位疫苗临床试验获批后，预计研发进展将加速，可能在2026年下半年开始贡献利润。此外，2025年上半年公司新流腺三联苗等产品获新兽药注册，显示出公司在多领域的新品布局潜力。随着非瘟疫苗的研发突破和市场开拓，公司将迎来新的成长动能。四、财务预测调整与估值分析受研发费用增加等因素影响，公司下调了2025年的业绩预测，但上调了2026-2027年的盈利预期。预计2025-2027年归母净利润分别为1.88亿、3.52亿和5.08亿元，对应EPS分别为0.17元、0.31元和0.45元，当前股价对应PE分别为56.7倍、30.3倍和21.0倍。基于非瘟疫苗的潜在市场前景，维持“买入”评级。五、风险提示报告提到的主要风险包括猪价上涨不及预期、非瘟疫苗研发进度不及预期以及市场竞争加剧。这些因素可能对公司未来业绩表现产生重要影响，投资者需密切关注相关动态。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552461692","isCrawlerRequest":true}